CDKN2A and adenocarcinoma: (22) previously identified three gene expression subgroups within KRAS-mutated adenocarcinomas, and reported that these subgroups were independently associated with co-mutation genomic alterations in KRAS and the tumor suppressor genes TP53, STK11, or CDKN2A. In our study, patients with such co-mutations demonstrated similar treatment effects in PFS and tumor size changes relative to the ITT population (Figure S3).